Fred Hutch consultants spotlight analysis on most cancers remedy advances, survivorship and precision oncology at ASCO


On the 2023 American Society for Medical Oncology Annual Assembly—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Most cancers Heart consultants will current analysis spanning survivorship, advances in remedies and scientific trials, how entry to most cancers care impacts outcomes, integrative drugs and extra.

Featured Fred Hutch shows and poster classes are listed beneath; for a full listing of Fred Hutch analysis at ASCO and the dates and instances of shows, please go to our web site. For media inquiries at ASCO, please contact Claire Hudson at [email protected] You’ll be able to comply with our researchers on Twitter #ASCO23 and go to us at sales space #4023.

Equitable entry to most cancers care

Dr. Hiba Khan will current an oral summary assessing the impression of monetary misery, as evidenced in credit score data, on most cancers survival. Researchers in Fred Hutch’s Hutchinson Institute for Most cancers Outcomes Analysis, or HICOR, discovered that sufferers with most cancers who skilled extreme hostile monetary occasions, reminiscent of third-party collections, delinquent mortgage funds, tax liens, foreclosures or repossessions inside two years of prognosis had been at increased threat for mortality after adjusting for sociodemographic and scientific components.

Further analysis on well being fairness and entry consists of:

  • An evaluation exhibiting that hostile monetary occasions resulted in elevated well being care utilization and larger per-patient prices at finish of life, in a poster session from led by Dr. Natasha Kwendakwema of HICOR.
  • Dr. Scott Ramsey and the HICOR group adopted most cancers sufferers utilizing smartwatches and apps to observe signs and biometric information throughout remedy. In a poster session, they share that in comparison with commercially-insured most cancers sufferers, financially fragile and Medicaid-insured sufferers had considerably increased common coronary heart charges, distinctive signs and repeat signs.
  • A examine revealing well being disparities in entry to molecular testing that inform using focused therapies in sufferers with superior stage non-small cell lung most cancers. In a poster session led by Dr. Lauren Shih, HICOR researchers discovered testing charges had been lowest amongst Hispanic sufferers, older sufferers, males and folks with Medicaid insurance coverage.
  • A poster session, led by Qin Solar of HICOR, during which researchers discovered underuse of germline testing in sufferers with prostate, pancreas and ovarian cancers, regardless of guideline suggestions. Lack of germline testing not solely can have an effect on remedy, it’s additionally a missed alternative to establish genetic threat components in relations.

Medical trials and remedy advances

Dr. Noam Kopmar and colleagues sought to know the potential advantage of including an antibody drug conjugate to frontline remedy to deal with sufferers with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma. In an oral presentation, Dr. Kopmar will clarify findings that including the antibody drug was not solely protected, however response charges in sufferers had been among the many highest reported to this point and plenty of sufferers had been in a position to proceed to bone marrow transplant.

In a SWOG Most cancers Analysis Community evaluation, introduced in an oral summary by Dr. Megan Othus, a analysis group discovered {that a} widespread system for measuring tumor development in scientific trials didn’t adequately correspond to outcomes in sufferers with uncommon cancers handled with checkpoint inhibitors within the S1609 DART trial. These findings are in step with comparable research of using this measuring system in sufferers handled with chemotherapy.

In an oral presentation, Dr. Shailender Bhatia will current findings from a Section 2 scientific trial in metastatic Merkel cell carcinoma sufferers that assessed nivolumab monotherapy and nivolumab plus ipilimumab mixture in two non-randomized cohorts respectively. The outcomes don’t counsel extra profit from nivolumab plus ipilimumab on this affected person inhabitants, opposite to a latest publication that had reported 100% response charge with mixture remedy.

Consultants will share extra from the next remedy research:

  • A five-year comply with up examine combining customary of care plus a checkpoint inhibitor in sufferers with diffuse giant B cell lymphoma, supporting potential inclusion of checkpoint inhibitors in first line DLBCL remedy and exploring the function of PD-L1 as a predictive biomarker in a poster session led by Dr. Carrie Ho.
  • How combining hypofractionated radiation with checkpoint inhibitors might profit sufferers with metastatic salivary gland cancers, in a poster session led by Dr. Cristina Rodriguez.
  • Outcomes from a Section 1 examine testing the mix of anti-CD73 and anti-PD-L1 monoclonal antibodies to deal with metastatic pancreatic ductal adenocarcinoma that discovered the routine was protected and indicated a pattern towards improved outcomes, led by Dr. Andrew Coveler in a poster session.
  • Dr. Laura Samples and collaborators characterised the challenges in utilizing CAR T-cell remedy to deal with sufferers with relapsed or refractory Burkitt lymphoma, a uncommon and extremely aggressive B-cell lymphoma, in a poster session.
  • Outcomes from a survey performed by an American Society of Medical Oncology and Pals of Most cancers Analysis activity drive, chaired by Dr. Joseph Unger, confirmed that methods reminiscent of distant distribution of oral remedy, distant consenting and distant symptom monitoring had been generally adopted by main most cancers scientific trial sponsors in the course of the COVID-19 pandemic. Findings shall be introduced in a poster session.
  • Led by Dr. Bart Scott, in a poster session, researchers discovered that general survival charges for sufferers with acute myeloid leukemia weren’t impacted in the course of the pandemic, however that elevated COVID-19 charges within the U.S. correlated with fewer transfusions, in-person visits and assessments for stem cell transplant.
  • Components related to sturdy response from a five-year comply with up in sufferers who obtained CD19 CAR T-cell remedy for relapsed and refractory continual lymphocytic leukemia, in a poster session led by Dr. Emily Liang.


Pediatric most cancers sufferers who obtain sure therapies are at an elevated threat of coronary heart illness later in life. Dr. Eric Chow will current an oral summary of a Youngsters’s Oncology Group examine that discovered a greater technique to foretell which pediatric most cancers sufferers will develop coronary heart illness years after remedy. Prediction fashions that incorporate standard coronary heart measurements could possibly precisely establish childhood most cancers sufferers at excessive threat of creating coronary heart illness inside 2-5 years, giving care groups a possible window of alternative to supply remedies that may gradual or cease coronary heart illness development.

Precision oncology

Dr. Manoj Menon will share insights in a poster session from a examine that performed molecular testing on breast most cancers tumors from sufferers on the Uganda Most cancers Institute. The analysis group discovered a various vary of mutations and prevalence of BRCA1, BRCA2 and PIK3CA mutations that had been significantly increased than in different documented populations. This information may inform wider use of focused therapies in sub-Saharan Africa, the place breast most cancers is the commonest most cancers, and make the case for together with focused most cancers therapies within the World Well being Group’s Mannequin Listing of Important Medicines.

Dr. Ruben Raychaudhuri and collaborators investigated focused therapies for folks with metastatic castration resistant prostate most cancers (mCRPC) with DNA injury restore alterations in two research. One poster session will discover how mutations in DNA injury restore genes might have an effect on PSMA expression and response to PSMA focused radioligand remedy. A second poster session will element two-year comply with up outcomes from a single arm pilot examine additionally targeted on sufferers with DNA injury restore alterations. On this examine, researchers discovered that the addition of the DNA damaging agent carboplatin to plain of care docetaxel considerably improved response charges.

Integrative drugs

In sufferers with non-muscle-invasive bladder most cancers, researchers examined the feasibility and efficacy of in-office acupuncture to scale back ache and urinary signs throughout induction intravesical Bacillus Calmette-Guerin (BCG). In a poster session, led by Dr. Sarah Psutka, researchers noticed enhancements in urinary signs and a suggestion of a discount in ache scores over successive remedies within the sufferers who obtained acupuncture.